Herpes zoster: a potential risk associated with fingolimod treatment

Int J Dermatol. 2015 Sep;54(9):e373-5. doi: 10.1111/ijd.12878. Epub 2015 Jul 14.

Authors

Ander Mayor Ibarguren¹, Cristina Gómez Fernández¹, Antonio Tallón Barranco², Mireya Fernández Fournier², Jéssica González Ramos¹, María P Romero Gómez³, Pedro Herranz Pinto¹

Affiliations

¹ Department of Dermatology, La Paz University Hospital, Madrid, Spain.
² Department of Neurology, La Paz University Hospital, Madrid, Spain.
³ Department of Microbiology, La Paz University Hospital, Madrid, Spain.

PMID: 26173466
DOI: 10.1111/ijd.12878

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acyclovir / analogs & derivatives
Acyclovir / therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Fingolimod Hydrochloride / adverse effects*
Fingolimod Hydrochloride / therapeutic use
Follow-Up Studies
Herpes Zoster / chemically induced*
Herpes Zoster / drug therapy
Herpes Zoster / pathology
Humans
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use
Middle Aged
Multiple Sclerosis / diagnosis
Multiple Sclerosis / drug therapy*
Recurrence
Risk Assessment
Treatment Outcome
Valacyclovir
Valine / analogs & derivatives
Valine / therapeutic use

Substances

Immunosuppressive Agents
Fingolimod Hydrochloride
Valine
Valacyclovir
Acyclovir